This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Estrogen receptor
From Proteopedia
| Line 41: | Line 41: | ||
**[[5krh]] - hERα LBD + NCAO2 peptide + benzylidene estrone<br /> | **[[5krh]] - hERα LBD + NCAO2 peptide + benzylidene estrone<br /> | ||
**[[5kri]], [[5krj]], [[5krk]], [[5krl]], [[5krm]], [[5kro]] - hERα LBD (mutant) + NCAO2 peptide + anti-hormone<br /> | **[[5kri]], [[5krj]], [[5krk]], [[5krl]], [[5krm]], [[5kro]] - hERα LBD (mutant) + NCAO2 peptide + anti-hormone<br /> | ||
| - | **[[5kcf]], [[5kct]], [[5kcu]], [[5kcw]], [[5kd9]], [[5kcc]], [[5kcd]] - hERα LBD (mutant) + NCAO2 peptide + OBHS derivative<br /> | + | **[[5kcf]], [[5kct]], [[5kcu]], [[5kcw]], [[5kd9]], [[5kcc]], [[5kcd]], [[4zn9]], [[4znh]], [[4zns]], [[4znt]], [[4znu]], [[4znv]], [[4znw]] - hERα LBD (mutant) + NCAO2 peptide + OBHS derivative<br /> |
**[[5kr9]] - hERα LBD (mutant) + NCAO2 peptide + coumestrol<br /> | **[[5kr9]] - hERα LBD (mutant) + NCAO2 peptide + coumestrol<br /> | ||
**[[5krf]] - hERα LBD (mutant) + peptide + anti-hormone<br /> | **[[5krf]] - hERα LBD (mutant) + peptide + anti-hormone<br /> | ||
Revision as of 10:07, 8 May 2017
| |||||||||||
For more details see
Ivan Koutsopatriy estrogen receptor
C-di-GMP receptors with PilZ domain
For more details on ERβ see Student Project 10 for UMass Chemistry 423 Spring 2015
For more details on ER-Tamoxifen complex see Tamoxifen.
3D structures of estrogen receptor
Updated on 08-May-2017
Reference
- ↑ Li MJ, Greenblatt HM, Dym O, Albeck S, Pais A, Gunanathan C, Milstein D, Degani H, Sussman JL. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators. J Med Chem. 2011 Apr 7. PMID:21473635 doi:10.1021/jm200192y

